Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma

Piorczynski, T. B., Ryu, Y. K., Pazos, M., Huang, W., Tolu, S. S., Estrella, B., & Amengual, J. E. (2023). Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 4391–4391. https://doi.org/10.1182/blood-2023-179271
Authors:
Ted B. Piorczynski
Yun Kyoung Ryu
Manuel Pazos
Wenxuan Huang
Seda S. Tolu
Brian Estrella
Jennifer E. Amengual
Affiliated Authors:
Ted B. Piorczynski
Yun Kyoung Ryu
Manuel Pazos
Wenxuan Huang
Seda S. Tolu
Brian Estrella
Jennifer E. Amengual
Columbia Affiliation:
Subjects:
Natural Killer Cells in Immunity (OpenAlex Topic)
Role of Histone Deacetylases in Cellular Regulation (OpenAlex Topic)
Protein Arginine Methylation in Mammals (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2023-179271
DOI:
10.1182/blood-2023-179271
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: